Target intelligence / Profile preview

Intestinal mucosal barrier and immune system

Molecular classification
Other
01

Overview

The intestinal mucosal barrier and immune system constitute a complex physiological entity essential for maintaining homeostasis by balancing nutrient absorption with protection against luminal pathogens. The physical barrier is composed of a specialized epithelial layer maintained by tight junction proteins, such as claudins and occludin, and a protective mucus layer (Vancamelbeke & Vermeire, 2017). Beneath this, the gut-associated lymphoid tissue (GALT) coordinates immune tolerance and active defense through a network of T cells, B cells, and dendritic cells (Okumura & Takeda, 2017). Dysregulation of this environment, characterized by increased permeability and chronic inflammation, is a central driver in the pathogenesis of inflammatory bowel disease (IBD), celiac disease, and various systemic inflammatory conditions (Turner, 2009). While not a single molecular target, this system is modulated by drugs that target specific components like integrins or cytokines to restore barrier function and immune balance (Chelakkot et al., Experimental & molecular medicine, 2018).

Other names
Gut barrierIntestinal mucosal barrierGut-associated lymphoid tissueGALTIntestinal immune environment
02

Mechanism of action

Therapeutic strategies involve modulating leukocyte trafficking to the gut mucosa (e.g., via α4β7 integrin antagonism), neutralizing pro-inflammatory cytokines (e.g., TNF-alpha, IL-12/23), and enhancing the structural integrity of epithelial tight junctions to restore barrier function (Turner, J. R., Nature reviews. Immunology, 2009; Vancamelbeke & Vermeire, Therapeutic advances in gastroenterology, 2017).

03

Biological functions

Immune responseOther
04

Disease associations

InflammationInfectionOther
05

Safety considerations

Increased risk of opportunistic infectionsPotential for impaired mucosal healingSystemic immunosuppressionDisruption of the gut microbiome
06

Interacting drugs

Vedolizumab

4 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinCitrullineSecretory IgALipopolysaccharide-binding protein

Beyond the preview

Go deeper on Intestinal mucosal barrier and immune system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal mucosal barrier and immune system.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call